{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:01:42Z","timestamp":1790395302159,"version":"4.1.0"},"reference-count":12,"publisher":"Japanese Society of Internal Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2169\/internalmedicine.7929-26","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T22:12:06Z","timestamp":1790028726000},"source":"Crossref","is-referenced-by-count":0,"title":["A Case of Acute Lymphoblastic Leukemia Developing After a Diagnosis of Myelodysplastic Syndrome Following Lenalidomide Therapy for Multiple Myeloma"],"prefix":"10.2169","author":[{"given":"Takayuki","family":"Nakamura","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Mouri","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimi","family":"Maehiro","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Semba","sequence":"additional","affiliation":[{"name":"Division of Precision Medicine, Kyushu University Faculty of Medicine Graduate School of Medical Science, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Umeda","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinobu","family":"Fukuyama","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Yamasaki","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuki","family":"Oya","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Maeda","sequence":"additional","affiliation":[{"name":"Division of Precision Medicine, Kyushu University Faculty of Medicine Graduate School of Medical Science, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Nagafuji","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Poh C, Keegan T, Rosenberg AS. Second primary malignancies in multiple myeloma: a review. Blood Rev 46: 100757, 2021.","DOI":"10.1016\/j.blre.2020.100757"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Saleem K, Franz J, Klem ML, et al. Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis. Lancet Haematol 9: e906-e918, 2022.","DOI":"10.1016\/S2352-3026(22)00289-7"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Geyer MB, Shaffer BC, Bhatnagar B, et al. Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawal. Blood Adv 7: 3087-3098, 2023.","DOI":"10.1182\/bloodadvances.2022009212"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Ribera JM. Therapy-related acute lymphoblastic leukemia. Haematologica 103: 1581-1583, 2018.","DOI":"10.3324\/haematol.2018.200311"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Aldoss I, Capelletti M, Park J, et al. Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma. Leukemia 33: 266-270, 2019.","DOI":"10.1038\/s41375-018-0213-y"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Palumbo A, Bringhen S, Kumar SK, et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol 15: 333-342, 2014.","DOI":"10.1016\/S1470-2045(13)70609-0"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Morice PM, Khalife-Hachem S, Sassier M, et al. Acute lymphoblastic leukemia in patients treated with lenalidomide for multiple myeloma: a safety meta-analysis of randomized controlled trials combined with a retrospective study of the WHO\u2019s pharmacovigilance database. Blood Cancer J 14: 177, 2024.","DOI":"10.1038\/s41408-024-01154-z"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Sperling AS, Gibson CJ, Ebert BL. The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia. Nat Rev Cancer 17: 5-19, 2017.","DOI":"10.1038\/nrc.2016.112"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Jaiswal S, Ebert BL. Clonal hematopoiesis in human aging and disease. Science 366: 6465, 2019.","DOI":"10.1126\/science.aan4673"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 360: 470-480, 2009.","DOI":"10.1056\/NEJMoa0808253"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Marke R, van Leeuwen FN, Scheijen B. The many faces of IKZF1 in B-cell precursor acute lymphoblastic leukemia. Haematologica 103: 565-574, 2018.","DOI":"10.3324\/haematol.2017.185603"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Stanulla M, Dagdan E, Zaliova M, et al. IKZF1(plus) defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric B-cell precursor acute lymphoblastic leukemia. J Clin Oncol 36: 1240-1249, 2018.","DOI":"10.1200\/JCO.2017.74.3617"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7929-26\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:32:46Z","timestamp":1790393566000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7929-26\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":12,"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7929-26","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"7929-26"}}